Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.
Executive Summary
Chemopreventive agents should show at least a 30% reduction in the number of precancerous adenomas to be associated with a benefit in colorectal cancer risk reduction, FDA's Gastrointestinal Drugs Advisory Committee suggested March 19
You may also be interested in...
FDA Drug Risk Evaluation Deputy Avigan Is Gastrointestinal Specialist
CDER Division of Drug Risk Evaluation Deputy Director Mark Avigan, MD, has expertise in gastrointestinal safety issues
FDA Drug Risk Evaluation Deputy Avigan Is Gastrointestinal Specialist
CDER Division of Drug Risk Evaluation Deputy Director Mark Avigan, MD, has expertise in gastrointestinal safety issues
Celebrex Data Requested By FDA May Clarify Cancer Risk Reduction Potential
FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.